PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report

BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachdeva, Manavi, Ngoi, Natalie Y L, Lim, Diana, Poon, Michelle L M, Thian, Yee Liang, Lim, Yi Wan, Lim, Siew Eng, Tong, Pearl, Lum, Jeffrey H Y, Ng, Joseph, Ilancheran, Arunachalam, Domingo, Efren J, Low, Jeffrey J H, Tan, David S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254584/
https://www.ncbi.nlm.nih.gov/pubmed/34234460
http://dx.doi.org/10.2147/OTT.S309661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254584/
https://www.ncbi.nlm.nih.gov/pubmed/34234460
http://dx.doi.org/10.2147/OTT.S309661

Ejemplares similares